Ethinyl estradiol; levonorgestrel - Generic Drug Details

What are the generic sources for ethinyl estradiol; levonorgestrel and what is the scope of patent protection?

Ethinyl estradiol; levonorgestrel is the generic ingredient in fifty-five branded drugs marketed by Agile, Glenmark Pharms Ltd, Avion Pharms, Lupin Ltd, Novast Labs, Aurobindo Pharma Ltd, Xiromed, Naari Pte, Watson Labs, Dr Reddys Labs Sa, Aurobindo Pharma, Teva Branded Pharm, Wyeth Pharms Inc, Sun Pharm, Exeltis Usa Inc, Cadence Health, Duramed Pharms Barr, Barr, Bayer Hlthcare, Wyeth Pharms, Novast Labs Ltd, Amneal Pharms, Hetero Labs, and Ph Health, and is included in seventy-six NDAs. There are six patents protecting this compound and five Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Ethinyl estradiol; levonorgestrel has sixty-seven patent family members in twenty countries.

Twenty-three suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for ethinyl estradiol; levonorgestrel

International Patents:	67
US Patents:	6
Tradenames:	55
Applicants:	24
NDAs:	76
Finished Product Suppliers / Packagers:	23
Clinical Trials:	74
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ethinyl estradiol; levonorgestrel
DailyMed Link:	ethinyl estradiol; levonorgestrel at DailyMed

Recent Clinical Trials for ethinyl estradiol; levonorgestrel

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	PHASE2
HIV Prevention Trials Network	PHASE2
Atea Pharmaceuticals, Inc.	PHASE1

See all ethinyl estradiol; levonorgestrel clinical trials

Generic filers with tentative approvals for ETHINYL ESTRADIOL; LEVONORGESTREL

Applicant	Application No.	Strength	Dosage Form
		0.03MG,0.01MG; 0.15MG,N/A	TABLET;ORAL
		0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ethinyl estradiol; levonorgestrel

Drug Class	Estrogen Progestin Progestin-containing Intrauterine System
Mechanism of Action	Estrogen Receptor Agonists
Physiological Effect	Inhibit Ovum Fertilization

Anatomical Therapeutic Chemical (ATC) Classes for ethinyl estradiol; levonorgestrel

G03AC	Progestogens
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03AD	Emergency contraceptives
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for ETHINYL ESTRADIOL; LEVONORGESTREL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BALCOLTRA	Tablets	ethinyl estradiol; levonorgestrel	0.1 mg/0.02 mg	208612	1	2020-07-14
QUARTETTE	Tablets	ethinyl estradiol; levonorgestrel	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg	204061	1	2013-07-10
LOSEASONIQUE	Tablets	ethinyl estradiol; levonorgestrel	0.1 mg/0.02 mg and 0.01 mg	022262	1	2009-11-16
SEASONIQUE	Tablets	ethinyl estradiol; levonorgestrel	0.15 mg/0.03 mg/0.01 mg	021840	1	2008-01-22
LYBREL	Tablets	ethinyl estradiol; levonorgestrel	0.09 mg/0.02 mg	021864	1	2007-10-05
SEASONALE	Tablets	ethinyl estradiol; levonorgestrel	0.15 mg/0.03 mg	021544	1	2004-03-29

US Patents and Regulatory Information for ethinyl estradiol; levonorgestrel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Barr	LEVONORGESTREL AND ETHINYL ESTRADIOL	ethinyl estradiol; levonorgestrel	TABLET;ORAL-21	075862-001	Apr 29, 2003		DISCN	No	No
Lupin Ltd	LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL	ethinyl estradiol; levonorgestrel	TABLET;ORAL	091674-001	Oct 26, 2011	AB	RX	No	No
Duramed Pharms Barr	ENPRESSE-28	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	075809-002	Jul 16, 2001	AB	RX	No	No

Expired US Patents for ethinyl estradiol; levonorgestrel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Avion Pharms	BALCOLTRA	ethinyl estradiol; levonorgestrel	TABLET;ORAL	208612-001	Jan 9, 2018
Teva Branded Pharm	SEASONALE	ethinyl estradiol; levonorgestrel	TABLET;ORAL	021544-001	Sep 5, 2003
Teva Branded Pharm	NORDETTE-28	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	018782-001	Jul 21, 1982

International Patents for ethinyl estradiol; levonorgestrel

Country	Patent Number	Title	Estimated Expiration
China	101801321	Dermal delivery device with in situ seal
Japan	2014159468	DERMAL DELIVERY DEVICE WITH IN SITU SEAL
Eurasian Patent Organization	201070123	УСТРОЙСТВО ДОСТАВКИ В КОЖУ С ИЗОЛИРУЮЩИМ СЛОЕМ IN SITU

Supplementary Protection Certificates for ethinyl estradiol; levonorgestrel

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
1214076	49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612

Ethinyl estradiol; levonorgestrel Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Ethinyl Estradiol and Levonorgestrel?

The combination of ethinyl estradiol and levonorgestrel is a widely used oral contraceptive. The market is influenced by demographic shifts, consumer preferences, regional healthcare policies, and the availability of generic options.

Market Size and Growth

• Global Value: The global oral contraceptives market was valued at approximately $8.5 billion in 2022[1].
• CAGR: The compound annual growth rate (CAGR) from 2023-2030 is forecast at about 4.2%, driven by increasing acceptance in emerging markets.
• Regional Distribution:
  • North America and Europe account for roughly 60% of sales owing to high contraceptive awareness and healthcare infrastructure.
  • Asia-Pacific is the fastest-growing segment, expected to expand at a CAGR of 6% during 2023-2030, propelled by rising urbanization and female workforce participation[2].

Market Drivers

• Increasing awareness about reproductive health.
• Government policies promoting contraceptive use.
• Expanding availability of generic formulations reducing prices.
• Rising contraceptive use among adolescents and women of reproductive age.

Market Restraints

• Concerns over side effects and safety.
• Strict regulatory approvals in some regions.
• Cultural and religious barriers in certain markets.

Competitive Landscape

• Major pharmaceutical companies like Bayer, Teva, and Pfizer dominate.
• Generics account for nearly 70% of global sales, emphasizing price sensitivity.
• Patent expirations for key formulations since 2010 have introduced increased competition.

What Is the Financial Trajectory of Ethinyl Estradiol and Levonorgestrel?

Financial performance aligns with broader contraceptive market trends, with specific variations based on formulation, regional sales, and patent status.

Revenue Trends

• Product Sales:
  • Dominant formulations generate annual revenues exceeding $2 billion globally.
  • Variations in formulations and dosing schedules impact sales volume.
• Pricing Dynamics:
  • Prices range from $10 to $50 per cycle, depending on region and brand.
  • Generic versions decrease prices by up to 60%, fueling market volume.

R&D and Licensing

• Investment in new delivery systems (e.g., patches, implants) is minimal compared to other drug classes.
• Licensing agreements for biosimilar versions aim to expand access in emerging markets.

Profitability and Cost Structure

• Gross margins typically range from 50% to 70%.
• Manufacturing costs are low relative to R&D expenses, which are mainly limited to formulation development and regulatory compliance.
• Regulatory costs for approval in different countries vary but generally represent a small percentage of sales.

Future Financial Outlook

• Market forecasts suggest steady growth with potential acceleration from new formulations and increasing regulation in emerging markets.
• Increased adoption of long-acting reversible contraceptives (LARCs) may impact oral contraceptive sales.
• Price competition may pressure margins, especially in regions with high generic penetration.

How Do Regulatory Policies Affect Market and Financial Dynamics?

• Regulatory approvals influence the launch timeline and market exclusivity.
• Stringent safety and efficacy standards in the US and Europe have led to more rigorous clinical evaluation, increasing compliance costs.
• Asian and Latin American markets exhibit variable regulatory frameworks, affecting entry strategies and pricing.

What Are the Key Challenges and Opportunities?

Challenges

• Safety concerns and regulatory hurdles.
• Competition from new contraceptive modalities.
• Cultural barriers limiting adoption.

Opportunities

• Developing next-generation formulations with improved safety profiles.
• Expanding access via biosimilars and generics.
• Penetrating underserved markets with tailored offerings.

Key Takeaways

• The global market for ethinyl estradiol and levonorgestrel-based contraceptives is growing steadily at about 4.2% CAGR.
• North America and Europe lead sales; Asia-Pacific shows rapid growth driven by demographic trends.
• Generic competition accounts for significant revenue share, exerting downward pressure on prices.
• The financial outlook remains positive, with growth fueled by new formulations and expanding access, though margins may decline due to pricing pressures.
• Regulatory environment and cultural factors present both challenges and opportunities for market expansion.

FAQs

1. How does patent expiration influence the market for ethinyl estradiol and levonorgestrel?

Patent expirations enable the entry of generic versions, increasing competition and decreasing prices, which boosts overall market volume but compresses profit margins for branded formulations.

2. Are there significant regional differences in contraceptive market regulation?

Yes. Regulatory frameworks in North America and Europe are stringent, requiring extensive clinical data, whereas emerging markets often have faster approval processes but variable quality controls.

3. What technological innovations are currently impacting the contraceptive market?

Development of long-acting reversible contraceptives (LARCs), delivery via transdermal patches, and monthly injectables aim to improve adherence and convenience.

4. How vulnerable is the market to safety concerns associated with hormonal contraceptives?

Safety concerns, including risks of blood clots and other side effects, influence regulatory policies and consumer preferences, impacting sales and prompting continuous monitoring.

5. What role do societal attitudes play in the growth of these contraceptives?

Cultural and religious barriers limit adoption in some regions, but increased awareness and education support growth in markets with supportive policies and societal acceptance.

References

[1] MarketsandMarkets. "Oral Contraceptives Market," 2022.

[2] Grand View Research. "Contraceptive Drugs Market Analysis," 2023.